Polymer drug-eluting stents: Is the future biodegradable?

The Lancet

Volumn 378, Issue 9807, 2011, Pages 1900-1902

  Waksman, Ron ^a   Maluenda, Gabriel ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLACTIN; POLYLACTIC ACID; POLYLACTIDE; POLYMER; RAPAMYCIN; UMIROLIMUS;

BIODEGRADABILITY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; STENT THROMBOSIS;

EID: 82755189863     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61706-6     Document Type: Note

References (11)

1. GG Stefanini, B Kalesan, PW Serruys et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 2011 10.1016/S0140-6736(11)61672-3 published online Nov 9.
2. B Lagerqvist, SK James, U Stenestrand et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019 (Pubitemid 46376801)
3. G Nakazawa, E Ladich, AV Finn, R Virmani Pathophysiology of vascular healing and stent mediated arterial injury EuroIntervention 4 2008 5 10
4. G Nakazawa, F Otsuka, M Nakano et al. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
5. S Windecker, PW Serruys, S Wandel et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
6. TA Ahmed, SC Bergheanu, T Stijnen, JW Plevier, PH Quax, JW Jukema Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review EuroIntervention 7 2011 505 516
7. RA Byrne, A Kastrati, S Massberg et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
8. A de Waha, A Dibra, RA Byrne et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 2011 371 377
9. KW Park, IH Chae, DS Lim et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary Intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher To Reduce Late Loss After Stenting) randomized trial J Am Coll Cardiol 58 2011 1844 1854
10. S Silber, S Windecker, P Vranckx, PW Serruys Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
11. PC Smits, E Kedhi, KJ Royaards et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18